Advertisement
Advertisement
U.S. markets close in 1 hour 38 minutes
Advertisement
Advertisement
Advertisement
Advertisement

HOOKIPA Pharma Inc. (HOOK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.4700+0.0200 (+1.38%)
As of 02:10PM EDT. Market open.
Advertisement

HOOKIPA Pharma Inc.

350 Fifth Avenue
72nd Floor Suite 7240
New York, NY 10118
United States
431 890 6360
https://www.hookipapharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees131

Key Executives

NameTitlePayExercisedYear Born
Mr. Joern AldagCEO & Director815.58kN/A1959
Dr. Reinhard Kandera Ph.D.CFO & Director577.83kN/A1969
Prof. Rolf M. Zinkernagel M.D., Ph.D.Co-FounderN/AN/A1944
Mr. Andreas BergthalerCo-FounderN/AN/AN/A
Mr. Lukas FlatzCo-FounderN/AN/AN/A
Ms. Christine D. Baker M.B.A.Chief Operating OfficerN/AN/A1965
Dr. Klaus Orlinger Ph.D.Chief Scientific OfficerN/AN/A1978
Ms. Marine PopoffCommunications & Investor Relations Mang.N/AN/AN/A
Mr. Matthew L. S. BeckExec. Director of Investor RelationsN/AN/AN/A
Mr. Michael SzumeraExec. Director of CommunicationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

Corporate Governance

HOOKIPA Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement